COP-BLAM regimen combined with XXXX and high-grade @entity1893 .

@entity1 @entity1261 @entity401 @entity281 @entity158 @entity1893 @entity221
The clinical efficacy of COP-BLAM chemotherapy combined with @entity1 recombinant @entity1261 ( @entity1261 ) was evaluated in 104 previously untreated @entity1 with @entity1893 ( @entity1893 ). According to the method of Laurence et al., a modified COP-BLAM regimen was administered every 21 days. @entity1261 was added when the granulocyte count fell below 1000 x 10(9)/l. Ninety-eight of 104 (94.2%) @entity1 achieved a complete remission; the 4-year survival rate was 82.4% with a median duration of observation of 26 months. Survival was significantly longer in @entity1 with low serum LDH levels, B-cell type or low CRP or in earlier clinical stages, than in @entity1 with high serum LDH levels, T-cell type of higher CRP levels or in advanced clinical stages. The mean duration of administration of @entity1261 was 5.4 days. Twelve @entity1 developed @entity281 during treatment. The adverse effects of @entity1261 included @entity401 , @entity158 and @entity221 . @entity1 administered COP-BLAM combined with @entity1261 achieved a high rate of remission and had a low incidence of @entity281 . Nearly all the @entity1 could be treated in 21-day cycles. The results suggest that @entity1261 combined with COP-BLAM was effective in treating @entity1893 , because the @entity1 can tolerate a higher dose of the anticancer agents.
